# EDGAR Filing Document

**Accession Number:** 0001385818
**File Stem:** 0001437749-25-037389
**Filing Date:** 2025-12
**Character Count:** 6973
**Document Hash:** a54ce89e971c026dac8142cd31698e6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-037389.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001437749-25-037389

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251210

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AYTU BIOPHARMA, INC
- **CENTRAL INDEX KEY:** 0001385818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 470883144
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38247
- **FILM NUMBER:** 251561999

**BUSINESS ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237
- **BUSINESS PHONE:** (720) 437-6580

**MAIL ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC.
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rosewind CORP
- **DATE OF NAME CHANGE:** 20070110

?xml version='1.0' encoding='ASCII'? aytu20251204_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**December 10, 2025**

Date of Report (Date of earliest event reported):

![logo01.jpg](logo01.jpg)

**AYTU BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38247** | **47-0883144** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**7900 East Union Avenue**, **Suite 920**

**Denver**, **CO 80237**

(Address of principal executive offices, including zip code)

**(**720**) **437-6580**

(Registrant's telephone number, including area code)

**Not applicable** 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| **Common Stock**, par value $0.0001 per share** | **AYTU** | **The**Nasdaq** Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On December 10, 2025, Aytu BioPharma, Inc. (the "Company") held its 2026 annual meeting of stockholders ("2026 Annual Meeting"). At the close of business on October 13, 2025, the record date for the 2026 Annual Meeting, there were 10,188,208 shares of the Company's common stock issued and outstanding with each share being entitled to one vote and to be voted together as one class at the 2026 Annual Meeting. At the 2026 Annual Meeting, there were present in person or by proxy 6,083,713 shares of the Company's common stock, representing stockholders entitled to vote of approximately 60% of the total issued and outstanding on the record date and constituting a quorum.

Set forth below are the voting results for the three proposals considered and voted upon at the 2026 Annual Meeting, all of which were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the United States Securities and Exchange Commission on October 24, 2025:

***Proposal No. 1 - Election of Directors***

The Company's stockholders elected all of the incumbent directors that stood for reelection. Each director was elected by a majority vote. The directors elected and the final vote tabulation for each director is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Director** | **Votes Cast For** | **Votes Cast For** | **Votes Withheld** | **Votes Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| Joshua R. Disbrow |  | 3192818 |  | 351123 |  | 2539772 |
| John A. Donofrio, Jr. |  | 3269350 |  | 274591 |  | 2539772 |
| Carl C. Dockery |  | 3210190 |  | 333751 |  | 2539772 |
| Abhinav "Abi" Jain |  | 3455220 |  | 88721 |  | 2539772 |
| Vivian H. Liu |  | 3454342 |  | 89599 |  | 2539772 |

---

***Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm***

The Company's stockholders approved the proposal to ratify the appointment by the Company's Audit Committee of Grant Thornton LLP, as the Company's independent registered public accounting firm for the fiscal year ended June 30, 2026. The final vote tabulation for this proposal is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes Cast For** | **Votes Cast Against** | **Votes Cast Abstain** | **Broker Non-Votes** |
| 5,783,905 | 257,411 | 42,397 | **─** |

---

***Proposal No. 3 - Advisory Vote on Executive Compensation***

The Company's stockholders approved, by a non-binding advisory vote, the proposal regarding executive compensation. The final vote tabulation for this proposal is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes Cast For** | **Votes Cast Against** | **Votes Cast Abstain** | **Broker Non-Votes** |
| 3,193,511 | 311,200 | 39,230 | 2,539,772 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AYTU BIOPHARMA, INC. | AYTU BIOPHARMA, INC. |
| Date: December 10, 2025 | By: | /s/ Ryan J. Selhorn |
|  |  | Ryan J. Selhorn |
|  |  | Chief Financial Officer |

---